Login to Your Account



Phase I Trial Begins

Atterocor’s Adrenal Cancer Bid: Victory Where IGF-1s Couldn’t?

By Randy Osborne
Staff Writer

Wednesday, October 16, 2013
Climbing into the ring with one of the harder – albeit rare – cancers to beat, Atterocor Inc. started a Phase I trial with ATR-101, designed to selectively cause apoptosis in adrenal cell carcinoma (ACC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription